RESUMO
A 23-year-old male patient, who suffers from beta-thalassemia major, came to us for an endocrine-metabolic evaluation. Medical history showed a diagnosis of heart disease with heart failure since the age of 16, type 1 diabetes mellitus diagnosed at the age of 18, treated with an intensive insulin therapy with a poor glycometabolic control. Patient performed regular blood transfusions and iron chelation with deferasirox. An echocardiogram revealed an enlarged left ventricle. Patient had undergone a comprehensive study of buoyancy both basal and hormone-stimulated and it was therefore carried out a diagnosis of GH deficiency and hypogonadotropic hypogonadism. A recombinant GH replacement therapy was then prescribed. After six months of therapy, the patient reported a net improvement of asthenic symptoms. Physical examination showed a reduction in abdominal adiposity in waist and an increase of 5 cm in stature. Laboratory tests showed an amelioration of glycometabolic control, such as to justify a reduction in daily insulin dose. The stature observed was thought appropriate to begin the administration of testosterone. Moreover, the cardiological framework showed a reduction of left ventricular dilatation, good ventricular motility, global minimum persistent tricuspid but not mitral regurgitation and no alteration on ECG.
Assuntos
Astenia/etiologia , Diabetes Mellitus Tipo 1/etiologia , Insuficiência Cardíaca/etiologia , Hormônio do Crescimento Humano/deficiência , Hipogonadismo/complicações , Sobrecarga de Ferro/etiologia , Talassemia beta/complicações , Transfusão de Sangue , Fármacos Cardiovasculares/uso terapêutico , Terapia por Quelação , Terapia Combinada , Diabetes Mellitus Tipo 1/tratamento farmacológico , Diabetes Mellitus Tipo 1/metabolismo , Nanismo/tratamento farmacológico , Nanismo/etiologia , Hormônio do Crescimento/uso terapêutico , Insuficiência Cardíaca/tratamento farmacológico , Humanos , Hipogonadismo/diagnóstico , Hipogonadismo/tratamento farmacológico , Insulina/administração & dosagem , Insulina/uso terapêutico , Quelantes de Ferro/uso terapêutico , Masculino , Insuficiência da Valva Mitral/etiologia , Testosterona/uso terapêutico , Insuficiência da Valva Tricúspide/etiologia , Adulto Jovem , Talassemia beta/tratamento farmacológico , Talassemia beta/terapiaRESUMO
IVIG (Intravenous immunoglobulin) have significantly improved the prognosis and the quality of life of immunodeficient patients and are routinely used as substitutive therapy. Transient hypogammaglobulinemia of infancy (THI) is a primary humoral immunodeficiency characterized by a transient IgG defect, but is not considered as a disease that justifies substitutive treatment and thus the use of IVIG as an alternative to antibiotic prophylaxis remains controversial also in symptomatic children. We treated 13 THI children severely symptomatic with IVIG (400mg/kg/every 3 weeks ) for a limited period (2 or 3 months) and followed them for 1 to 3 years. During the follow-up, the frequency of overall infections decreased approximately tenfold (from 0.39 to 0.047 infection/month per child) and no severe infections were reported. Although this study lacks untreated controls, the results suggest that the observed clinical improvement is correlated to IVIG therapy. Furthermore, our study suggests that the infused IVIG have no long-term effect on endogenous IgG production and do not lengthen the immunodeficiency condition since all children produced a normal amount of specific IgG in response to vaccination carried out 5 months after the end of infusions. In conclusion, our results suggest that IVIG may stop the vicious circle of infection-immunodeficiency and should be considered as a first line therapy in highly symptomatic THI children.